Key result
Recombinant human GH therapy at doses of 0.6 and 1.2 IU/day increased serum IGF-I into the normal range after 12 weeks in adults with growth hormone deficiency.
Why the study?
Does recombinant human GH therapy at different low starting doses improve serum IGF-I and IGFBP-3 levels in adults with growth hormone deficiency?
Population
60 patients with growth hormone deficiency, aged 20-70 years, including both childhood-onset and adult-onset…
Comparison
Recombinant human GH therapy at varying doses… vs Comparison between the three different dose…
Design
RCT, Randomized to one of the three dose groups
Follow-up
12 weeks
Authors
Loading...
Low-dose GH may elevate IGF-I/IGFBP-3 in GHD; leaves open optimal regimens and long-term outcomes.
RCT (n=60)
randomized
Does recombinant human GH therapy at different low starting doses improve serum IGF-I and IGFBP-3 levels in adults with growth hormone deficiency?
A low starting dose of 0.6 to 1.2 IU/day of recombinant human GH is sufficient to normalize serum IGF-I levels in adults with growth hormone deficiency.
Janssen et al. (1997) conducted an RCT in Growth hormone deficiency (GHD) (n=60). Recombinant human GH (Genotropin) vs. Different dose groups was evaluated on Serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3). Recombinant human GH therapy at doses of 0.6 and 1.2 IU/day increased serum IGF-I into the normal range after 12 weeks in adults with growth hormone deficiency.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: